40 results about "Cerebral haemorrhages" patented technology

The present invention provides a therapeutic agent containing as an active ingredient an HGF gene used for therapy of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, spinal cord injury, diabetic peripheral neuritis, and ischemic cerebrovascular disorders (cerebral infarction, cerebral haemorrhage, etc.) More specifically, the present invention provides a therapeutic agent for neurodegenerative diseases, containing a hepatocyte growth factor (HGF) gene as an active ingredient.

The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (e.g. human Factor VIIa) and a buffering agent; wherein the molar ratio of non-complexed calcium ions (Ca²⁺) to the Factor VII polypeptide is lower than 0.5. The composition may further comprise a stabilizing agent (e.g. copper or magnesium ions, benzamidine, or guanidine), a non-ionic surfactant, a tonicity modifying agent, an antioxidant and a preservative. The composition is useful for treating a Factor VII-responsive syndrome, such as bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor XI deficiency, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy.

An orally taken enteric Chinese medicine in the form of tablet, capsule, dripping pill, or soft capsule for treating unstable angina pectoris, acute myocardial infarction, cerebral haemorrhage, etc and preventing deep phlebothrombosis is prepared from leech. Its preparing process is also disclosed.

The invention discloses application of a whole hemp extract in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases. The whole hemp extract is prepared by evenly mixing 0.3-99.7 parts of an industrial hemp and fructus cannabis extract and 0.3-99.7 parts of an industrial hemp and cannabis sativa L extract. Experiments prove that the whole hemp extract has the effects of improving the activity of SOD, GSH-PX and other anti-free-radical enzymes, scavenging free radicals and protecting cardio and cerebral blood vessels and tissues and preventing and controlling occurrence and development of the cardiovascular and cerebrovascular diseases. The whole hemp extract can be used for preparing the drugs for preventing and treating the cardiovascular and cerebrovascular diseases, such as cerebral ischemia, myocardial ischemia, neuronal damage caused by hypoxia-reoxygenation, cerebral infarction (stroke), cerebral thrombosis, cerebral hemorrhage, a coronary heart disease and myocardial infarction and has the good application prospect in treatment or prevention of the cardiovascular and cerebrovascular diseases.

The invention discloses an external Chinese medicinal composition for treating motor dysfunction and a preparation method thereof. Its raw materials include Chinese medicinal materials such as calamus calamus, maple lotus, ivy, windproof, and multiflorum multiflorum; compared with the prior art, the present invention has obvious characteristics in principles, methods, prescriptions, and medicines, and is mainly used for stroke (cerebral hemorrhage) , cerebral infarction, etc.) and brain atrophy caused by paralysis, limb numbness, muscle atrophy, motor dysfunction, etc. have preventive and therapeutic effects. The present invention adopts medicine for external use combined with massage therapy, and in the course of medication, adjusts medication according to the specific condition of the patient, so as to achieve the best therapeutic effect.

The invention discloses application of salvianolic acid A in preparation of a drug for treating cerebral hemorrhage. Cerebral hemorrhage comprises simple cerebral hemorrhage stroke, hemorrhage after cerebral embolism and hemorrhage caused by thrombolytic drug treatment and other factors. Experimental research finds that salvianolic acid A can significantly reduce the cerebral infarction volume andencephaledema of rats, improve neurological functions and protect blood-brain barrier damage caused by thrombolytic drugs such as t-PA, thereby reducing the risk and degree of hemorrhagic transformation when the thrombolytic drugs are used. The salvianolic acid A can be used for preparing the drug for treating cerebral hemorrhage and hemorrhage caused by thrombolytic drug treatment, relieving secondary hemorrhage in ischemic areas and improving prognosis of patients.

A strawberry fruit-honey beverage is proportionally prepared from strawberry fruit, honey and VC through washing and cutting strawberry fruits to obtain small blocks, squeezing to obtain juice, mixing it with honey and VC, boiling at 70-80 deg.C for 30 min, and cooling. It can be used to prevent enterogastric disease, anemia and scurvy, and treat hypertension, hypercholesteremia, atherosclerosis, coronary heart disease and cerebral haemorrhage.

New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

Peptides and derivatives or analogs thereof are provided for having β-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.

The invention relates to a medicine field, in particular relates to application of (Z)-1-methyl-1, 5-dihydro-2-amido-5-(4-(mesyl) benzal)-4H-imidazole-4-ketone and pharmaceutically acceptable salt thereof in the treatment of cardiovascular and cerebrovascular diseases of mammals; the compound and the salt of the compound can effectively prohibit formation of thrombus and are used for preventing or curing diseases such as coronary heart disease, atherosclerosis, artery and vein thrombosis, angina, myocardial infarction, coronary heart disease, myocarditis, ischemic cardiomyopathy, myocardial infarction, cardiovascular complications of diabetes, cerebral haemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, brain stroke, lacunar infarction, transient ischemic attack, cerebral arteriosclerosis and peripheral vascular diseases such as obstructive vasculitis, aortoarteritis, hypercholesterolemia, or high blood lipids, etc.

A composite Chinese medicine in the form of dripping pill and soft capsule for treating cerebral arteriosclerosis, ischemic cerebral apoplexy and cerebral haemorrhage sequelae, and its preparing process are disclosed.

The invention relates to mulberry leaf tea and a preparation technology thereof. The raw materials of the mulberry leaf tea mainly comprise 50-100 parts of frosted mulberry leaves, 10-20 parts of folium eucommiae, 10-30 parts of oat, 30-50 parts of soybeans and 10-30 parts of chrysanthemums. The mulberry leaf tea is prepared through the following steps of cleaning the raw materials, drying the cleaned materials, crushing the dried materials, and performing mixing. According to the mulberry leaf tea prepared by the technology, the mouth feel is improved, the blood sugar is effectively reduced, diabetes is prevented, blood viscosity is reduced, and miocardial infarction and cerebral haemorrhage are effectively prevented from generating.

The invention relates to a medicament for treating brain injury sequelae. The medicament is prepared by the following substances in ratios by weight: 50-100 parts of blood centipede, 50-150 parts of panax japonicus, 50-100 parts of edible tulip and 10-20 parts of asarum insigne diels. The medicament for treating brain injury sequelae disclosed by the invention can treat traumatic brain injury sequelae, cerebral haemorrhage, oedema, dizziness and headache.

The invention discloses an application of an effective component group of a thrombus-eliminating collateral-dredging formula in preparation of a medicine for treating cerebral hemorrhage. The cerebralhemorrhage comprises simple cerebral hemorrhage stroke, cerebral ischemia hemorrhage caused by hyperglycemia or hypertension after cerebral embolism, and hemorrhage caused by thrombolytic medicine treatment and other factors. Experimental research finds that an effective component group formed by active screening of components obtained by different extraction methods of the thrombus-eliminating and collateral-dredging formula can significantly reduce the volume of cerebral infarction and encephaledema of rats, improve neurological functions and protect blood-brain barrier damage caused by hyperglycemia, thereby reducing the risk and degree of hemorrhagic transformation during hyperglycemia. The effective component group of the thrombus-eliminating and collateral-dredging formula can be used for preparing medicines for treating cerebral hemorrhage and hemorrhage transformation caused by hyperglycemia, relieving secondary hemorrhage in ischemic areas and improving prognosis of patients.

The invention aims to provide traditional Chinese medicine for treating cerebral apoplexy. The traditional Chinese medicine is characterized by comprising the following medicine: salvia miltiorrhiza, violet magnolia, evening primrose, kudzuvine root, ligusticum wallichii, kelp, mustard leaf, radix et herba rumicis maritimi, asarum, rhizoma anemarrhenae, achyranthis root, hemerocallis fulva Linn., bee pollen, gingko, pomelo, tangerine, orange, lychee, lemon, banana, borneol, and camellia oil, wherein salvia miltiorrhiza, violet magnolia, evening primrose, kudzuvine root, ligusticum wallichii, kelp, and mustard leaf serve as monarch drugs to perform the efficacies of activating blood circulation to expel bruises, clearing channels to relieve pain, eliminating annoyance, and refreshing; radix et herba rumicis maritimi, asarum, rhizoma anemarrhenae, achyranthis root, hemerocallis fulva Linn., and bee pollen serve as ministerial drugs to perform the efficacies of tonifying deficiency, dredging blood vessels, and stabilizing blood pressure; gingko, pomelo, tangerine, orange, lychee, lemon, banana, borneol, and camellia oil serve as adjuvant drugs contributing to human body vasoconstriction. All the medicine are combined to achieve the efficacy of repairing cranial nerves, so as to not only fast dissolve thrombus and dredge blood vessels to recover normal blood circulation, but also can feed nutrition to damaged brain cells continuously, activate the activity of the damaged brain cells, and quickly recover the conduction function of the cranial nerves. Therefore, the traditional Chinese medicine can be used for effectively treating symptoms such as cerebral apoplexy, cerebral thrombosis, cerebral infarct and cerebral haemorrhage.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

The present invention provides new medicine preparation and new therapy. The icy water Chinese medicine preparation of the present invention can kill bacteria, eliminate various foreign matter in blood vessels, regulate and improve the functions of internal organs and cure various diseases radically. The said preparation may be used in treat cerebral haemorrhage, cerebral thrombus, cerebral infarction, sciatica, protrusion of lumber intervertebral disc and many other diseases with high curative effect.

The invention discloses cerebral micro-hemorrhage treatment equipment in the technical field of cerebral micro-hemorrhage treatment equipment. The cerebral micro-hemorrhage treatment equipment comprises the following steps: step 1, selecting 36 cerebral hemorrhage patients, and dividing the 36 patients into a test group and a control group, wherein 18 patients are in each group; and step 2, applying conventional drug treatment to all patients by referring to domestic and foreign guidelines, and adding upper limb ischemia adaptation training treatment to the patients in the test group on the basis of conventional treatment. Aiming at the current situation that cerebral micro-hemorrhage lacks effective treatment measures, the cerebral micro-hemorrhage treatment equipment is based on a human body endogenous protection theory, and provides a simple, convenient, feasible, safe, noninvasive and easy-to-popularize treatment means for accelerating brain injury repair after cerebral micro-hemorrhage from the perspective of improving the brain injury repair ability.